Avoro Calls Merck's $180/sh Offer for Acceleron Pharma (XLRN) Inadequate; Urges Shareholders Not to Tender
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
November 9, 2021 5:31 PM ESTBelieves Now Is the Wrong Time to Cash out of Acceleron, Given Companys Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data
Sees Continuing as Standalone Entity as Clearly Superior Path for Acceleron
Highlights What It Believes Was a Flawed and Inadequate Sale Process, Including Not Pursuing Other Strategic Alternatives
Avoro Stands Ready to Support an Independent Acceleron
NEW YORK--(BUSINESS WIRE)-- Avoro Capital Advisors (Avoro), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its... More
